Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Regeneron a Growth Biotech Play - Analyst Blog
Nov 06, 2008 11:49 AM
- Best Perfomers Over Last Quarter
Oct 06, 2008 02:19 AM
- Analyst Comments: DIRECTV, Regeneron, Kimco, ASR, Atmel
Aug 06, 2008 08:31 AM
- Analyst Comments: Tractor Supply, McGraw-Hill, Regeneron, Hasbro, Eclipsys
Jul 15, 2008 09:00 PM
- Biotech Exhibiting a Quiet Strength
Jun 25, 2008 10:14 PM
- Stay Confident About Biotech
Jun 12, 2008 01:20 AM
- Biotech Continues to Outperform
May 30, 2008 01:34 AM
- UPDATE: Regeneron Shares Drop On Failed Cancer Study
May 21, 2008 12:12 PM
- UPDATE: Regeneron Shares Drop On Failed Cancer Study
May 21, 2008 12:12 PM
- Sanofi-Aventis: Aflibercept Didn't Reach Endpoint In Study
May 21, 2008 03:11 AM
- Regeneron Announces Presentation at the 20th Annual Piper Jaffray Healthcare Conference
Dec 01, 2008 09:32 AM
- Regeneron Announces Presentation at the Credit Suisse 2008 Healthcare Conference
Nov 10, 2008 09:49 AM
- Zacks Analyst Blog Highlights: Coca-Cola Hellenic Bottling Co., Regeneron Pharmaceuticals, Inc., Denbury Resources Inc., Kinross Gold Corp. And Trimeris, Inc.
Nov 07, 2008 12:32 PM
- Regeneron Reports Third Quarter 2008 Financial and Operating Results
Nov 04, 2008 07:01 AM
- VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeting
Sep 28, 2008 03:01 PM
- Regeneron Announces Presentation at the UBS Global Life Sciences Conference
Sep 19, 2008 09:31 AM
- Regeneron and Columbia University Enter Into a Strategic VelocImmune(R) Agreement to Discover Human Monoclonal Antibodies
Sep 16, 2008 08:21 AM
- Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Sep 05, 2008 09:30 AM
- Regeneron's ARCALYST(R) (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering Therapy
Sep 03, 2008 06:07 AM
- Regeneron Announces Webcast Presentation of Results from Phase 2 Study of ARCALYST(R) (rilonacept) in Gout Patients Initiating Urate-Lowering Therapy
Sep 02, 2008 06:46 PM
- Form 4 REGENERON PHARMACEUTICAL For: Oct 01 Filed by: McCorkle Douglas S (10K)
Oct 03, 2008 12:44 PM
- Form 4 REGENERON PHARMACEUTICAL For: Aug 20 Filed by: GOLDSTEIN JOSEPH L (10K)
Oct 02, 2008 04:23 PM
- Form 4 REGENERON PHARMACEUTICAL For: Sep 29 Filed by: SCHLEIFER LEONARD S (10K)
Oct 01, 2008 05:25 PM
- Form 4 REGENERON PHARMACEUTICAL For: Jun 13 Filed by: VAGELOS P ROY (10K)
Sep 25, 2008 05:25 PM
- Form 4 REGENERON PHARMACEUTICAL For: Sep 19 Filed by: KOLINSKI STUART (10K)
Sep 22, 2008 05:31 PM
- Form 4 REGENERON PHARMACEUTICAL For: Sep 22 Filed by: ROBERTS WILLIAM (10K)
Sep 22, 2008 05:31 PM
- Form 4 ROBERTS WILLIAM For: Aug 22 (10K)
Sep 18, 2008 05:18 PM
- Form 4 REGENERON PHARMACEUTICAL For: Sep 09 Filed by: BROWN MICHAEL S (10K)
Sep 10, 2008 03:02 PM
- Form 4 REGENERON PHARMACEUTICAL For: Aug 11 Filed by: GOLDSTEIN JOSEPH L (10K)
Aug 15, 2008 01:41 PM
- Form 4 REGENERON PHARMACEUTICAL For: May 30 Filed by: SHOOTER ERIC M (10K)
Jun 03, 2008 02:27 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
REGN
|
Compare to S&P
|
| YTD |
-35.98 %
|
4.88 %
|
| 4 Weeks |
-19.90 %
|
-13.42 %
|
| 12 Weeks |
-18.93 %
|
12.37 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -22.73 %
|
|
EPS Growth in Last Year: 50.00 %
|
|
Sales Growth in Last Quarter: 8.13 %
|
|
Sales Growth in Last Quarter: 193.95 %
|
|
|
